Posts tagged sales and marketing
BTIG starts Fulgent Genetics at buy

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a ‘buy” rating and $15 price target. The stock closed at $8.86 on Friday.

“While the genetic testing market is not without challenges and competition is formidable, we believe Fulgent’s proprietary technology platform drives multiple sustainable competitive advantages, including a broad and flexible test menu and an attractive cost structure,” writes analyst Karen Koski.

Read More
BioLight expands portfolio with eye drops for DES

BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.

The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel Aviv University.

Read More